Triple-blind clinical trial on the effect of a combination of garlic, silymarin and curcumin in comparison with placebo in the treatment of non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190602043787N1

Enrollment

Registered

2019-08-09

Start date

2019-07-01

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group:The intervention group received routine treatment with low intake of carbohydrate and fat with the administration of curcumin. garlic, silymarin in Soft gel , will

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: increased LFT plus sonographic evidenses of NAFLD age between 18-70 years

Exclusion criteria

Exclusion criteria: diabetes mellitus hypothyioidism any drug users sever cardiac disease or sever polmunary disease or past medical history of liver disease,cirrhosis,cancer pregnancy and lactation abnormal test include:ANA,HCV Ab,HBC Ab,HBS Ag,Anti TTG IgA,TIBC,Ferritin,SI,ASMA,seroloplasmin

Design outcomes

Primary

Measure	Time frame
1.decrease in serum level of ALT. Timepoint: at the baseline and 3 months after intervention. Method of measurement: autoanalyzer bt3000.	—

Secondary

Measure	Time frame
Decrease in ultrasonographic grading. Timepoint: at the baseline and 3 months after intervention. Method of measurement: ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Ataee

Mashhad University of Medical Sciences

zahraataee57@gmail.com+98 51 3854 3031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026